Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
AKBA 
Akebia Ther (AKBA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/30/2025: AKBA (4-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $5.4
1 Year Target Price $5.4
| 3 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 0.33% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 421.93M USD | Price to earnings Ratio - | 1Y Target Price 5.4 |
Price to earnings Ratio - | 1Y Target Price 5.4 | ||
Volume (30-day avg) 4 | Beta 0.31 | 52 Weeks Range 1.45 - 4.08 | Updated Date 12/31/2025 |
52 Weeks Range 1.45 - 4.08 | Updated Date 12/31/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.08 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -7.07% | Operating Margin (TTM) 7.57% |
Management Effectiveness
Return on Assets (TTM) 4.8% | Return on Equity (TTM) -553.45% |
Valuation
Trailing PE - | Forward PE 8.37 | Enterprise Value 308064928 | Price to Sales(TTM) 1.87 |
Enterprise Value 308064928 | Price to Sales(TTM) 1.87 | ||
Enterprise Value to Revenue 1.37 | Enterprise Value to EBITDA 14.51 | Shares Outstanding 265365993 | Shares Floating 260021522 |
Shares Outstanding 265365993 | Shares Floating 260021522 | ||
Percent Insiders 3.56 | Percent Institutions 49.86 |
Upturn AI SWOT
Akebia Ther
Company Overview
History and Background
Akebia Therapeutics, Inc. was founded in 2007. It is a biopharmaceutical company focused on the development and commercialization of innovative therapies for patients with kidney disease. A significant milestone was the development and FDA approval of Vafseo (vadadustat) for the treatment of anemia due to chronic kidney disease (CKD) in adult patients on dialysis. The company has undergone restructuring and strategic partnerships to advance its pipeline.
Core Business Areas
- Kidney Disease Therapeutics: Development and commercialization of small molecule drugs targeting unmet needs in patients with kidney disease, particularly focusing on anemia and other complications associated with chronic kidney disease.
Leadership and Structure
Akebia Therapeutics is led by a management team with expertise in the pharmaceutical industry. The organizational structure is typical of a biopharmaceutical company, with departments dedicated to research and development, clinical operations, regulatory affairs, commercialization, and corporate functions.
Top Products and Market Share
Key Offerings
- Product Name 1: Vafseo (vadadustat) - Description: An oral hypoxia-inducible factor (HIF) inhibitor approved for the treatment of anemia due to chronic kidney disease (CKD) in adult patients on dialysis. Market Share Data: Specific market share data for Vafseo is emerging as it is a relatively new entrant. Competitors: Roxadustat (Farxiga by AstraZeneca/FibroGen), epoetin alfa (Epogen by Amgen), darbepoetin alfa (Aranesp by Amgen).
Market Dynamics
Industry Overview
The kidney disease therapeutics market is characterized by a growing patient population due to the increasing prevalence of chronic kidney disease and diabetes. There is a continuous need for novel therapies that offer improved efficacy, safety, and convenience compared to existing treatments, particularly injectable erythropoiesis-stimulating agents (ESAs). The market is competitive with both established pharmaceutical companies and emerging biotechs developing innovative solutions.
Positioning
Akebia Therapeutics is positioned as a company focused on addressing the significant unmet medical needs in kidney disease. Its key strength lies in its development of oral HIF inhibitors, which offer a potential advantage over injectable treatments. The company's success hinges on the market adoption of Vafseo and the progression of its pipeline.
Total Addressable Market (TAM)
The TAM for CKD treatments, particularly anemia associated with CKD, is substantial and growing, estimated in the tens of billions of dollars globally. Akebia Therapeutics is positioned to capture a share of this market with its oral HIF inhibitor, Vafseo, aiming to provide an alternative to existing therapies. However, its current market penetration is limited by its relatively new product and the competitive landscape.
Upturn SWOT Analysis
Strengths
- Innovative oral HIF inhibitor (Vafseo) offering a potential treatment alternative.
- Focus on a significant and growing patient population with unmet needs in kidney disease.
- Experienced leadership team in the biopharmaceutical sector.
Weaknesses
- Limited commercial track record and brand recognition for Vafseo.
- Dependence on the success of a single lead product.
- Financial resources may be constrained compared to larger pharmaceutical companies.
- Potential for ongoing clinical or regulatory challenges.
Opportunities
- Growing prevalence of CKD and associated anemia.
- Potential for label expansion of Vafseo for non-dialysis CKD patients.
- Partnerships and collaborations to expand market reach and R&D capabilities.
- Development of next-generation therapies for kidney disease complications.
Threats
- Intense competition from established and emerging therapies.
- Pricing pressures and reimbursement challenges.
- Potential for adverse events or safety concerns with Vafseo.
- Changes in regulatory landscape for drug approvals.
- Patent expirations and generic competition in the long term.
Competitors and Market Share
Key Competitors
- AstraZeneca (AZN)
- Amgen (AMGN)
- AbbVie (ABBV)
Competitive Landscape
Akebia Therapeutics faces competition from well-established pharmaceutical companies with extensive resources and existing market presence in the nephrology space. Its competitive advantage lies in its oral HIF inhibitor technology, offering a potential differentiator in convenience. However, its newer status and reliance on Vafseo present challenges against established brands and strong sales forces of its competitors.
Growth Trajectory and Initiatives
Historical Growth: Historically, Akebia Therapeutics' growth has been driven by its R&D pipeline progression and clinical trial successes, culminating in the FDA approval of Vafseo. Revenue growth was minimal prior to commercialization.
Future Projections: Future growth projections are heavily dependent on the market uptake of Vafseo, potential regulatory approvals in new indications or geographies, and the successful development of other pipeline assets. Analyst estimates would typically focus on projected revenue growth for Vafseo and the path to profitability.
Recent Initiatives: Recent initiatives include the commercial launch of Vafseo, strategic partnerships, and ongoing efforts to expand its market presence and explore potential new indications or pipeline advancements.
Summary
Akebia Therapeutics is a biopharmaceutical company focused on kidney disease therapeutics, with its lead product being Vafseo. While it has a promising innovative therapy, it faces significant competition and financial challenges typical of companies in its stage. Key strengths include its targeted approach to an unmet medical need and its novel oral drug. Weaknesses lie in its limited commercial history and reliance on a single product. The company's future success hinges on market adoption of Vafseo and navigating the competitive landscape.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Investor Relations Filings (SEC)
- Financial News Outlets
- Industry Research Reports
- Biopharmaceutical Market Analysis
Disclaimers:
This JSON output is an analysis based on publicly available information and is for informational purposes only. It does not constitute financial or investment advice. Market share and financial data are estimates and subject to change. Users should conduct their own due diligence and consult with qualified financial professionals before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Akebia Ther
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 2014-03-20 | CEO, President & Director Mr. John P. Butler MBA | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 181 | Website https://www.akebia.com |
Full time employees 181 | Website https://www.akebia.com | ||
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD. The company is also developing AKB-9090 for treating cardiac surgery-related acute kidney injury and acute respiratory distress syndrome; and AKB-10108 for the treatment of retinopathy of prematurity in neonates. The company has license and collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of Vafseo in Japan and other Asian countries. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.